---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-23-003349"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T04:20:52.766535+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tonix reports FY2022 net loss of $116.9M; cash $120.2M; pipeline milestones ahead

## Summary
- Net loss $34.1M in Q4 2022 ($0.56/share) vs $29.6M ($2.08) in Q4 2021; FY net loss $116.9M ($3.27) vs $92.3M ($8.10).
- Cash and equivalents $120.2M at Dec 31, 2022, down from $178.7M a year ago; cash used in operations $98.1M in FY2022.
- Repurchased 15.7M shares under $12.5M program; new $12.5M program approved Jan 2023 with 1M shares bought.
- Interim analysis for Phase 3 fibromyalgia study (TNX-102 SL) expected Q2 2023; topline Q4 2023.
- Appointed R. Newcomb Stillwell to Board; acquired antiviral assets from Healion Bio; licensed monoclonal antibodies from Columbia.

## SEC filing metadata
- accession: 0001387131-23-003349
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000138713123003349/0001387131-23-003349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000138713123003349/tnxp-8k_031323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-23-003349
- JSON: https://secwatch.observer/filing/0001387131-23-003349.json
- Plain text: https://secwatch.observer/filing/0001387131-23-003349.txt

## Key facts
- Earnings Releases
  Tonix Pharmaceuticals Holding Corp. reported financial results for fourth quarter and full year ended December 31, 2022.
  - Period: fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 13, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000138713123003349/0001387131-23-003349-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.